132 related articles for article (PubMed ID: 21856161)
1. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
Jiang C; Yang L; Wu WT; Guo QL; You QD
Bioorg Med Chem; 2011 Sep; 19(18):5612-27. PubMed ID: 21856161
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors.
Dong JJ; Li QS; Liu ZP; Wang SF; Zhao MY; Yang YH; Wang XM; Zhu HL
Eur J Med Chem; 2013; 70():427-33. PubMed ID: 24184776
[TBL] [Abstract][Full Text] [Related]
3. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
[TBL] [Abstract][Full Text] [Related]
4. [Synthesis and antitumor activity of novel tetrahydro-beta-carboline derivatives as KSP inhibitors].
Ruan XQ; Chen M; Wu WT; You QD
Yao Xue Xue Bao; 2013 Jul; 48(7):1119-23. PubMed ID: 24133978
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and preclinical evaluation of new 5,6- (or 6,7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agents.
Chou LC; Tsai MT; Hsu MH; Wang SH; Way TD; Huang CH; Lin HY; Qian K; Dong Y; Lee KH; Huang LJ; Kuo SC
J Med Chem; 2010 Nov; 53(22):8047-58. PubMed ID: 20973552
[TBL] [Abstract][Full Text] [Related]
7. Novel ATP-competitive kinesin spindle protein inhibitors.
Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction.
Carbajales C; Prado MÁ; Gutiérrez-de-Terán H; Cores A; Azuaje J; Novio S; Nuñez MJ; Fernández-García B; Sotelo E; García-Mera X; Sánchez-Lazo P; Freire-Garabal M; Coelho A
Chembiochem; 2014 Jul; 15(10):1471-80. PubMed ID: 24943831
[TBL] [Abstract][Full Text] [Related]
9. CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity.
Jiang C; Yang L; Wu WT; Guo QL; You QD
J Pharm Pharmacol; 2011 Nov; 63(11):1462-9. PubMed ID: 21988427
[TBL] [Abstract][Full Text] [Related]
10. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
11. 3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
Gasparotto V; Castagliuolo I; Ferlin MG
J Med Chem; 2007 Nov; 50(22):5509-13. PubMed ID: 17915851
[TBL] [Abstract][Full Text] [Related]
12. [Synthesis and biological evaluation of tetrahydro-beta-carline derivatives].
Ruan XQ; You QD; Yang L; Wu WT
Yao Xue Xue Bao; 2008 Aug; 43(8):828-32. PubMed ID: 18956775
[TBL] [Abstract][Full Text] [Related]
13. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
[TBL] [Abstract][Full Text] [Related]
14. Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.
Coleman PJ; Schreier JD; Cox CD; Fraley ME; Garbaccio RM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Rickert K; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo L; Prueksaritanont T; Li C; Mahan EA; Fernandez-Metzler C; Salata JJ; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(19):5390-5. PubMed ID: 17761419
[TBL] [Abstract][Full Text] [Related]
15. Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.
Roecker AJ; Coleman PJ; Mercer SP; Schreier JD; Buser CA; Walsh ES; Hamilton K; Lobell RB; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo LC; Li C; Fernandez-Metzler C; Mahan EA; Prueksaritanont T; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(20):5677-82. PubMed ID: 17766111
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
Rodriguez D; Ramesh C; Henson LH; Wilmeth L; Bryant BK; Kadavakollu S; Hirsch R; Montoya J; Howell PR; George JM; Alexander D; Johnson DL; Arterburn JB; Shuster CB
Bioorg Med Chem; 2011 Sep; 19(18):5446-53. PubMed ID: 21855351
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 2-(3-alkylaminophenyl)-6-(pyrrolidin-1-yl)quinolin-4-ones as potent antitumor agents.
Huang SM; Cheng YY; Chen MH; Huang CH; Huang LJ; Hsu MH; Kuo SC; Lee KH
Bioorg Med Chem Lett; 2013 Feb; 23(3):699-701. PubMed ID: 23260351
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors.
Holland JP; Kang A; Cohrs S; Selivanova SV; Milicevic Sephton S; Betzel T; Frey D; Wieser M; Jaussi R; Kammerer RA; Schibli R; Fischer E
Chem Biodivers; 2013 Apr; 10(4):538-55. PubMed ID: 23576341
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
20. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
Garbaccio RM; Tasber ES; Neilson LA; Coleman PJ; Fraley ME; Olson C; Bergman J; Torrent M; Buser CA; Rickert K; Walsh ES; Hamilton K; Lobell RB; Tao W; South VJ; Diehl RE; Davide JP; Yan Y; Kuo LC; Li C; Prueksaritanont T; Fernandez-Metzler C; Mahan EA; Slaughter DE; Salata JJ; Kohl NE; Huber HE; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(20):5671-6. PubMed ID: 17804233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
